ARTICLE | Finance
Series B builds Locus’ spending power for business development
With $35M financing, Locus is searching for expansion opportunities for its CRISPR and bacteriophage platforms
May 18, 2022 11:31 AM UTC
Locus is eyeing business development opportunties in the down market, and plans to apply its $35 million in new equity financing to deals that expand the reach of its CRISPR-based antimicrobial platform into new indications — specifically microbiome applications.
On Wednesday, Locus Biosciences Inc. announced a series B round and conversion of a convertible note totaling $35 million. Investors included Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson & Johnson Innovation — JJDC Inc. and Discovery Innovations...